Sutro Biopharma, Inc. (FRA:S090)

Market Cap	107.20M -26.9%
Revenue (ttm)	90.04M -34.4%
Net Income	-184.75M
EPS	-22.05
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50
Average Volume	8
Open	13.20
Previous Close	13.00
Day's Range	12.50 - 13.30
52-Week Range	4.66 - 20.00
Beta	n/a
RSI	60.30
Earnings Date	Mar 27, 2026

About Sutro Biopharma

Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in P...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 178
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: S090

Financial Performance

In 2024, Sutro Biopharma's revenue was $62.04 million, a decrease of -59.64% compared to the previous year's $153.73 million. Losses were -$227.46 million, 113.0% more than in 2023.

Financial numbers in USD